ClinicalTrials.gg
RecruitingNCT06118983Updated Nov 16, 2026

Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)

An interventional study of I-TRANSFER-HF in Heart Failure, sponsored by Weill Medical College of Cornell University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Health services research

How we know

Updated Nov 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,094
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Heart Failure by Weill Medical College of Cornell University — 5 open to participants now, 5 under way, none of them phase 3. Heart Failure · Weill Medical College of Cornell University.

Planned enrollment
Largest of 12
1,094 · median 40
Started
2026
with 3 others
No phase
6 of 13
2 open now
Registered
9th of 13
by date

Among the 13 studies in Heart Failure by Weill Medical College of Cornell University, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, and was the 9th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 13 studies in Heart Failure by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Heart Failure by Weill Medical College of Cornell University, or all of them as a file.
02

Study summary

This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.

The study is interested in two questions:

  1. Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
  2. Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?

The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.

Read the detailed description

The investigators' will test two hypotheses:

Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.

Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • home health care
  • hospital-to-home transition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Aim 1, Inclusion Criteria:

  • Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.

Aim 1, Exclusion Criteria:

  • Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.

Aim 2, Inclusion Criteria:

- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.

Aim 2, Exclusion Criteria:

- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,094 participants (estimated)

Study arms

  • Experimental
    I-TRANSFER-HF

    This is a 1-year long intervention period when I-TRANSFER-HF is in operation.

    Other: I-TRANSFER-HF

  • No intervention
    Standard of Care (usual care)

    This is a baseline period of usual care (UC) with no intervention.

Interventions

  • OtherI-TRANSFER-HF

    I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US.

06

What researchers measure

Primary outcomes

  1. All-cause 30-day hospital readmission

    All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims

    Time frame: 30 days following post-Index HF Hospitalization

  2. Number of Eligible patients

    Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data

    Time frame: 12 months

  3. Number of Eligible Patients Who Received Protocol Components

    Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data

    Time frame: 12 months

  4. Modality of outpatient follow-up

    The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data

    Time frame: 12 months

  5. Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation

    The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data

    Time frame: 12 months

  6. Timeliness of Post-Hospital Outpatient Follow-Up

    The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data

    Time frame: 12 months

  7. Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)

    Feasibility will be assessed through qualitative interviews with site stakeholders

    Time frame: 30 days after intervention (year of intervention)

  8. Feasibility of implementing I-TRANSFER-HF (Surveys)

    Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention.

    Time frame: 30 days after intervention (year of intervention)

Secondary outcomes

  1. All-cause 30-day ED visits

    All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data

    Time frame: 30 days following post-Index heart failure Hospitalization.

  2. Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims

    Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit.

    Time frame: During a 12-month period (year of intervention)

  3. Acceptability of I-TRANSFER-HF - Qualitative Interviews

    Acceptability will be assessed through qualitative interviews.

    Time frame: 30 days after intervention (year of intervention)

  4. Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey

    Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention.

    Time frame: 30 days after intervention (year of intervention)

  5. Fidelity of I-TRANSFER-HF (Participant-Completed)

    Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process.

    Time frame: 30 days after intervention (year of intervention)

  6. Fidelity of I-TRANSFER-HF (Observational Ratings)

    Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process.

    Time frame: 30 days after intervention (year of intervention)

  7. Adaptation of I-TRANSFER-HF

    Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period.

    Time frame: 30 days after intervention (year of intervention)

07

Study locations

2 of 2 sites recruiting
  • VNS Health Partners in Care
    New York, New York 10017, United States
    Recruiting
  • Weill Cornell Medicine
    New York, New York 10021, United States
    Recruiting
    • Madeline R Sterling, MD, MPH, MS · Contactmrs9012@med.cornell.edu · 646-962-5029
    • Madeline R Sterling, MD, MPH, MS · Principal investigator
08

References and documents

Publications

  • Sterling MR, Espinosa CG, Spertus D, Shum M, McDonald MV, Ryvicker MB, Barron Y, Tobin JN, Kern LM, Safford MM, Banerjee S, Goyal P, Ringel JB, Rajan M, Arbaje AI, Jones CD, Dodson JA, Cene C, Bowles KH. Improving TRansitions ANd outcomeS for heart FailurE patients in home health CaRe (I-TRANSFER-HF): a type 1 hybrid effectiveness-implementation trial: study protocol. BMC Health Serv Res. 2024 Oct 1;24(1):1160. doi: 10.1186/s12913-024-11584-x. PubMed 39354472 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 8 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 7, 2023
StartActual
Nov 1, 2026was Jul 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 28, 2026→Nov 1, 2026
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Jul 28, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06118983
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Nov 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Madeline R Sterling, MD, MPH, MS
Contact
mrs9012@med.cornell.edu
6469625029
Madeline R Sterling, MD, MPH, MS
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion